Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.

Haematologica - 1 May 2013

Lange Thoralf, Edelmann Anja, Siebolts Udo, Krahl Rainer, Nehring Claudia, Jäkel Nadja, Cross Michael, Maier Jacqueline, Niederwieser Dietger, Wickenhauser Claudia

Abstract excerpt

The risk profile and prognosis of patients with myelofibrosis is well described by the Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell transplantation is considered for intermediate-2/high risk disease. However, indicators of prognosis after transplantation are still lacking. Seventy simultaneously collected pairs of trephine and blood samples were quantified for JAK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Recurrence

Share to Transplantation, Homologous

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23300178
DOI: 10.3324/haematol.2012.076901
PMCID: PMC3640116

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.PMID 23300178Read ↗

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.Semantic proximity Read ↗

Controversies and dilemmas in allogeneic transplantation for myelofibrosis.Semantic proximity Read ↗

JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatmentSemantic proximity Read ↗

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.Semantic proximity Read ↗

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.Semantic proximity Read ↗

The Importance of Confirming False Homozygosity in Pretransplant HLA Typing Results of Patients with Hematologic Malignancies.Semantic proximity Read ↗

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosisSemantic proximity Read ↗

A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.Semantic proximity Read ↗

Bone marrow transplant relapse with loss of an allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.